Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 13,095 shares at $55.17 ($723K) on 2016-01-15, disclosed to the SEC on 2016-01-19.
Open-market sale of $723k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.17 | 5,987 | $330K | 45.7% |
| 2 | $55.17 | 5,987 | $330K | 45.7% |
| 3 | $55.98 | 1,121 | $63K | 8.7% |
| Total | $55.24 avg | 13,095 | $723K | 100% |
| Filing → |
| KITE | SELL | 2017-07-06 | $1.0M | — | Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |